
Sign up to save your podcasts
Or
Interview with John Sims, author of Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
4.9
1212 ratings
Interview with John Sims, author of Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
129 Listeners
288 Listeners
315 Listeners
162 Listeners
98 Listeners
36 Listeners
485 Listeners
270 Listeners
9 Listeners
17 Listeners
18 Listeners
23 Listeners
83 Listeners
1,090 Listeners
1,320 Listeners
29 Listeners
184 Listeners
507 Listeners
321 Listeners
19 Listeners
360 Listeners
98 Listeners